The IBN SINA Pharmaceutical Industry PLC (DSE: IBNSINA)
Bangladesh
· Delayed Price · Currency is BDT 291.80
-6.40 (-2.15%)
At close: Nov 14, 2024
IBNSINA Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 - 2015 |
| Revenue | 11,371 | 11,371 | 9,125 | 8,480 | 7,376 | 6,192 | Upgrade
|
| Revenue Growth (YoY) | 24.61% | 24.61% | 7.61% | 14.96% | 19.13% | 17.62% | Upgrade
|
| Cost of Revenue | 6,839 | 6,839 | 5,254 | 4,914 | 4,275 | 3,595 | Upgrade
|
| Gross Profit | 4,532 | 4,532 | 3,871 | 3,566 | 3,101 | 2,597 | Upgrade
|
| Selling, General & Admin | 3,617 | 3,617 | 3,051 | 2,745 | 2,368 | 1,997 | Upgrade
|
| Operating Expenses | 3,617 | 3,617 | 3,051 | 2,745 | 2,368 | 1,997 | Upgrade
|
| Operating Income | 914.57 | 914.57 | 819.81 | 821.16 | 732.91 | 599.3 | Upgrade
|
| Interest Expense | -53.58 | -53.58 | -44.43 | -47.33 | -40 | -34.91 | Upgrade
|
| Interest & Investment Income | 4.13 | 4.13 | 2.37 | 3.33 | 2.46 | 0.92 | Upgrade
|
| Earnings From Equity Investments | - | - | - | -1.29 | -1.93 | -1.79 | Upgrade
|
| Currency Exchange Gain (Loss) | 7.26 | 7.26 | 11.15 | -2.83 | -0.2 | -1.09 | Upgrade
|
| Other Non Operating Income (Expenses) | 21.95 | 21.95 | 13.59 | 17.22 | 9.99 | 1.98 | Upgrade
|
| EBT Excluding Unusual Items | 894.34 | 894.34 | 802.5 | 790.27 | 703.23 | 564.4 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | 9.6 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.36 | 0.36 | 2.23 | - | 1.22 | 0.68 | Upgrade
|
| Pretax Income | 894.7 | 894.7 | 804.73 | 799.86 | 704.45 | 565.08 | Upgrade
|
| Income Tax Expense | 223.35 | 223.35 | 198.92 | 194.19 | 215.48 | 172.56 | Upgrade
|
| Earnings From Continuing Operations | 671.35 | 671.35 | 605.81 | 605.67 | 488.97 | 392.53 | Upgrade
|
| Minority Interest in Earnings | -0.83 | -0.83 | -0.39 | 0.19 | 0.15 | - | Upgrade
|
| Net Income | 670.52 | 670.52 | 605.42 | 605.87 | 489.12 | 392.53 | Upgrade
|
| Net Income to Common | 670.52 | 670.52 | 605.42 | 605.87 | 489.12 | 392.53 | Upgrade
|
| Net Income Growth | 10.75% | 10.75% | -0.07% | 23.87% | 24.61% | 16.73% | Upgrade
|
| Shares Outstanding (Basic) | 31 | 31 | 31 | 31 | 31 | 31 | Upgrade
|
| Shares Outstanding (Diluted) | 31 | 31 | 31 | 31 | 31 | 31 | Upgrade
|
| EPS (Basic) | 21.46 | 21.46 | 19.38 | 19.39 | 15.66 | 12.56 | Upgrade
|
| EPS (Diluted) | 21.46 | 21.46 | 19.38 | 19.39 | 15.66 | 12.56 | Upgrade
|
| EPS Growth | 10.75% | 10.75% | -0.07% | 23.87% | 24.61% | 16.73% | Upgrade
|
| Free Cash Flow | -174.62 | -174.62 | 472.99 | 53.4 | 309.64 | -114.94 | Upgrade
|
| Free Cash Flow Per Share | -5.59 | -5.59 | 15.14 | 1.71 | 9.91 | -3.68 | Upgrade
|
| Dividend Per Share | 6.300 | 6.300 | 6.000 | 6.000 | 4.700 | 3.850 | Upgrade
|
| Dividend Growth | 5.00% | 5.00% | 0% | 27.66% | 22.08% | 28.33% | Upgrade
|
| Gross Margin | 39.85% | 39.85% | 42.42% | 42.05% | 42.04% | 41.94% | Upgrade
|
| Operating Margin | 8.04% | 8.04% | 8.98% | 9.68% | 9.94% | 9.68% | Upgrade
|
| Profit Margin | 5.90% | 5.90% | 6.63% | 7.14% | 6.63% | 6.34% | Upgrade
|
| Free Cash Flow Margin | -1.54% | -1.54% | 5.18% | 0.63% | 4.20% | -1.86% | Upgrade
|
| EBITDA | 1,752 | 1,752 | 1,558 | 1,021 | 922.15 | 746.03 | Upgrade
|
| EBITDA Margin | 15.41% | 15.41% | 17.07% | 12.04% | 12.50% | 12.05% | Upgrade
|
| D&A For EBITDA | 837.65 | 837.65 | 738.18 | 199.57 | 189.24 | 146.73 | Upgrade
|
| EBIT | 914.57 | 914.57 | 819.81 | 821.16 | 732.91 | 599.3 | Upgrade
|
| EBIT Margin | 8.04% | 8.04% | 8.98% | 9.68% | 9.94% | 9.68% | Upgrade
|
| Effective Tax Rate | 24.96% | 24.96% | 24.72% | 24.28% | 30.59% | 30.54% | Upgrade
|
| Advertising Expenses | 56.57 | 56.57 | 45.9 | 47.72 | 42.36 | 28.28 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.